Pub Date : 2006-02-15DOI: 10.1017/S1748232105000091
L. Pope
{"title":"AVP-923 as a Novel Treatment for Pseudobulbar Affect in ALS","authors":"L. Pope","doi":"10.1017/S1748232105000091","DOIUrl":"https://doi.org/10.1017/S1748232105000091","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130873433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2006-02-15DOI: 10.1017/S1748232105000042
B. Stankoff, C. Lubetzki, M. Clanet
{"title":"Modafinil for the Treatment of Fatigue in Multiple Sclerosis","authors":"B. Stankoff, C. Lubetzki, M. Clanet","doi":"10.1017/S1748232105000042","DOIUrl":"https://doi.org/10.1017/S1748232105000042","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130286750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2006-02-15DOI: 10.1017/S1748232105000066
N. Wiendels, M. Ferrari
{"title":"Treating Migraine Attacks ASAP: Concept and Methodological Issues","authors":"N. Wiendels, M. Ferrari","doi":"10.1017/S1748232105000066","DOIUrl":"https://doi.org/10.1017/S1748232105000066","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114282550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2006-02-15DOI: 10.1017/S1748232105000121
Allison Lin, J. Bodkin
{"title":"Selegiline in the Treatment of Negative Symptoms of Schizophrenia","authors":"Allison Lin, J. Bodkin","doi":"10.1017/S1748232105000121","DOIUrl":"https://doi.org/10.1017/S1748232105000121","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131788353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.1017/S1748232105000108
E. Hollander, E. Swanson, E. Anagnostou, Ann T. Phillips, W. Chaplin, S. Wasserman
{"title":"Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism","authors":"E. Hollander, E. Swanson, E. Anagnostou, Ann T. Phillips, W. Chaplin, S. Wasserman","doi":"10.1017/S1748232105000108","DOIUrl":"https://doi.org/10.1017/S1748232105000108","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115636377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.1017/S1748232105000029
J. Cummings
In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology of brain disorders have led to increasingly sophisticated target identification that guides drug development. Advances in the basic neuroscience and disease mechanisms have been particularly obvious in the neurologic disorders where there is an ever improving understanding of the underlying mechanisms of brain function and brain disease. Progress in neurotherapeutics has occurred in concert with progress in basic science methodologies, neuroimaging, clinical trial design, and trial analysis. There is an increasing enthusiasm for clinical trials that provide highly credible data with which to guide evidence-based medicine. The United States Food and Drug Administration (US FDA) requires a close link between the clinical trial population tested and the specific indication for which the agent will be approved. This contributes to the proliferation of clinical trials, as industry sponsors of trials seek to expand the populations for which their products are indicated. An increasing number of patients and physicians are involved in clinical trials. Advancing clinical trial methodology has itself become a major endeavor.
{"title":"Introduction to Neurotherapeutics and Neuropsychopharmacology","authors":"J. Cummings","doi":"10.1017/S1748232105000029","DOIUrl":"https://doi.org/10.1017/S1748232105000029","url":null,"abstract":"In recent years there has been tremendous progress in advancing new treatments for neurologic and psychiatric illnesses. New agents have emerged for the treatment of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, migraine, schizophrenia, bipolar illness, depression, and substance abuse disorders. Advances in understanding of basic pathophysiology and molecular biology of brain disorders have led to increasingly sophisticated target identification that guides drug development. Advances in the basic neuroscience and disease mechanisms have been particularly obvious in the neurologic disorders where there is an ever improving understanding of the underlying mechanisms of brain function and brain disease. Progress in neurotherapeutics has occurred in concert with progress in basic science methodologies, neuroimaging, clinical trial design, and trial analysis. There is an increasing enthusiasm for clinical trials that provide highly credible data with which to guide evidence-based medicine. The United States Food and Drug Administration (US FDA) requires a close link between the clinical trial population tested and the specific indication for which the agent will be approved. This contributes to the proliferation of clinical trials, as industry sponsors of trials seek to expand the populations for which their products are indicated. An increasing number of patients and physicians are involved in clinical trials. Advancing clinical trial methodology has itself become a major endeavor.","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129834663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.1017/S174823210500011X
H. Meltzer
{"title":"Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial","authors":"H. Meltzer","doi":"10.1017/S174823210500011X","DOIUrl":"https://doi.org/10.1017/S174823210500011X","url":null,"abstract":"","PeriodicalId":347111,"journal":{"name":"Progress in Neurotherapeutics and Neuropsychopharmacology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125888736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：